Related Experiment Video
Updated: Mar 16, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Intensive atorvastatin improves endothelial function and decreases ADP-induced platelet aggregation in patients with
Xiaorong Xu1, Yu Liu1, Kuibao Li1
1Heart Center, Beijing Chaoyang Hospital affiliated to the Capital Medical University, China.
Insights
Intensive atorvastatin therapy improved endothelial function and platelet inhibition in ST-segment elevated myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI). This approach was well-tolerated and showed potential for reducing adverse cardiovascular events.
Area of Science:
- Cardiology
- Pharmacology
- Vascular Biology
Background:
- ST-segment elevated myocardial infarction (STEMI) is a critical cardiovascular condition.
- The role of intensive atorvastatin in STEMI patients requires further investigation regarding endothelial and platelet function.
- Current treatment guidelines for STEMI do not fully elucidate the benefits of high-dose statin therapy.
Purpose of the Study:
- To evaluate the acute effects of intensive atorvastatin (40mg) versus standard atorvastatin (20mg) on endothelial function and platelet activity in STEMI patients.
- To assess the impact of atorvastatin on serum endothelin-1 (ET-1) levels and ADP-induced platelet clot strength (MA-ADP).
- To determine the safety and tolerance of intensive atorvastatin therapy in this patient population.
Main Methods:
- A single-center, single-blinded, prospective randomized controlled trial was conducted.
- 120 STEMI patients undergoing primary PCI were randomized into intensive (60) and standard (60) atorvastatin groups.
- Serum ET-1 and MA-ADP were measured pre- and post-treatment; MA-ADP was assessed using thromboelastography.
Main Results:
- Intensive atorvastatin significantly reduced serum ET-1 levels (P<0.05) and MA-ADP (P<0.05) compared to standard therapy.
- No significant changes in LDL-C or CRP levels were observed in either group.
- While not statistically significant, the intensive group showed a trend towards fewer major adverse cardiovascular events.
Conclusions:
- Periprocedural intensive atorvastatin therapy enhances endothelial function and platelet inhibition in STEMI patients undergoing PCI.
- High-dose atorvastatin is well-tolerated in STEMI patients.
- Intensive atorvastatin may offer a protective benefit against adverse cardiovascular events in STEMI patients.
Background:
Intensive atorvastatin may be beneficial for patients with ST segment elevated myocardial infarction (STEMI). However, its effects on endothelial and residual platelet function remain uninvestigated in these patients.
Methods:
This single-center single-blinded prospective randomized controlled trial included STEMI patients undergoing PCI, aiming to investigate the acute effects of intensive atorvastatin (40mg) vs. standard atorvastatin (20mg) on serum endothelin-1 (ET-1) and ADP-induced platelet clot strength (MA-ADP), which were measured before and after 7days of atorvastatin treatment respectively. MA-ADP was measured by thromboelastography. The tolerance and safety of intensive atorvastatin therapy in these patients were also observed.
Results:
A total of 120 patients (60 patients in the intensive group and 60 patients in the standard group) with STEMI, who are undergoing primary PCI, were included into this study (mean age, 63.5years). Patients from these two groups were matched for baseline characteristics. Atorvastatin did not significantly affect the serum level of LDL-C or CRP in either the standard or intensive group. Furthermore, ET-1 did not significantly change following treatment with atorvastatin in the standard group. However, intensive treatment with atorvastatin significantly reduced ET-1 serum level (0.65±0.38pmol/L vs. 0.49±0.21pmol/L, P<0.05) and achieved a greater reduction of MA-ADP (49.2±12.1 vs. 38.4±17.4mm, P<0.05). In addition, although not statistically significant, patients assigned to the intensive group appeared to suffer from less major adverse cardiovascular events.
Conclusions:
Periprocedural intensive atorvastatin is associated with improved endothelial function and platelet inhibition, and is well-tolerated in STEMI patients undergoing PCI.
